Viatris Sets The Bar Low So There Will Eventually Be A Chance To Grow
Viatris' 2021 financial guidance was below investor expectations, suggesting a challenging road ahead for the newly formed company.
You may also be interested in...
Merck & Co. plans to spin off Organon in June as a diversified health care company focused on women's health, biosimilars and established products.
With a goal of reducing its cost base by at least $1bn by 2024, Viatris has delivered plans to significantly restructure its global manufacturing network. Up to 20% of Viatris’ 45,000-strong workforce could be impacted by the initiative which will see the firm close, divest or downsize 15 of its manufacturing plants around the globe.
With Mylan continuing to count down the days until its merger with Pfizer’s Upjohn completes, the US firm has struck a deal to acquire Aspen Pharmacare’s thrombosis business in Europe, bolstering what is already a $4bn operation.